{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T23:29:49Z","timestamp":1785886189114,"version":"3.56.0"},"reference-count":15,"publisher":"MDPI AG","issue":"1","license":[{"start":{"date-parts":[[2021,12,23]],"date-time":"2021-12-23T00:00:00Z","timestamp":1640217600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Vaccines"],"abstract":"<jats:p>Background: We here describe the case of a 71-year-old Caucasian woman previously diagnosed with Eosinophilic Granulomatosis with Polyangiitis (EGPA) that had been treated with Mepolizumab, an anti-IL5 monoclonal antibody, since 2019 with a good clinical response. Methods: She had a mild COVID-19 in December 2020 and she tested negative for SARS-CoV-2 infection in only late January 2021. In April 2021 she received the first dose of mRNA BNT162b2 vaccine. Ten days later she developed myalgia, dyspnea and numbness of the limbs due to a relapse of EGPA that occurred during Mepolizumab treatment.<\/jats:p>","DOI":"10.3390\/vaccines10010013","type":"journal-article","created":{"date-parts":[[2021,12,23]],"date-time":"2021-12-23T21:40:21Z","timestamp":1640295621000},"page":"13","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":20,"title":["Eosinophilic Granulomatosis with Polyangiitis Relapse after COVID-19 Vaccination: A Case Report"],"prefix":"10.3390","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2269-0439","authenticated-orcid":false,"given":"Giulia","family":"Costanzo","sequence":"first","affiliation":[{"name":"Department of Medical Sciences and Public Health, University of Cagliari, 09131 Cagliari, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea Giovanni","family":"Ledda","sequence":"additional","affiliation":[{"name":"Department of Medical Sciences and Public Health, University of Cagliari, 09131 Cagliari, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandra","family":"Ghisu","sequence":"additional","affiliation":[{"name":"Department of Medical Sciences and Public Health, University of Cagliari, 09131 Cagliari, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matteo","family":"Vacca","sequence":"additional","affiliation":[{"name":"Department of Medical Sciences and Public Health, University of Cagliari, 09131 Cagliari, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5768-391X","authenticated-orcid":false,"given":"Davide","family":"Firinu","sequence":"additional","affiliation":[{"name":"Department of Medical Sciences and Public Health, University of Cagliari, 09131 Cagliari, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4517-1749","authenticated-orcid":false,"given":"Stefano","family":"Del Giacco","sequence":"additional","affiliation":[{"name":"Department of Medical Sciences and Public Health, University of Cagliari, 09131 Cagliari, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2021,12,23]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1661","DOI":"10.1136\/annrheumdis-2020-218009","article-title":"Auto-antibodies related to systemic autoimmune rheumatic diseases in severely ill patients with COVID-19","volume":"79","author":"Vlachoyiannopoulos","year":"2020","journal-title":"Ann. Rheum. Dis."},{"key":"ref_2","first-page":"1","article-title":"Severe acute respiratory syndrome coronavirus-2-induced flare of systemic sclerosis","volume":"5","author":"Campochiaro","year":"2021","journal-title":"Scand. J. Rheumatol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1007\/s13167-017-0101-y","article-title":"Vaccination and autoimmune diseases: Is prevention of adverse health effects on the horizon?","volume":"8","author":"Vadala","year":"2017","journal-title":"EPMA J."},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Watad, A., De Marco, G., Mahajna, H., Druyan, A., Eltity, M., Hijazi, N., Haddad, A., Elias, M., Zisman, D., and Naffaa, M.E. (2021). Immunemediated disease flares or new-onset disease in 27 subjects following mrna\/DNA SARS-CoV-2 vaccination. Vaccines, 9.","DOI":"10.3390\/vaccines9050435"},{"key":"ref_5","first-page":"1","article-title":"COVID-19 mRNA vaccination leading to CNS inflammation: A case series","volume":"415","author":"Bhattacharyya","year":"2021","journal-title":"J. Neurol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2015\/258430","article-title":"Possible Triggering Effect of Influenza Vaccination on Psoriasis","volume":"2015","author":"Gunes","year":"2015","journal-title":"J. Immunol. Res."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.ejpn.2021.07.011","article-title":"Vaccination in acute immune-mediated\/inflammatory disorders of the central nervous system","volume":"34","author":"Bakhtadze","year":"2021","journal-title":"Eur. J. Paediatr. Neurol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1177\/0961203311429552","article-title":"Gulf War Syndrome as a part of the autoimmune (autoinflammatory) syndrome induced by adjuvant (ASIA)","volume":"21","author":"Israeli","year":"2012","journal-title":"Lupus"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1016\/j.kint.2021.05.017","article-title":"ANCA glomerulonephritis after the Moderna COVID-19 vaccination","volume":"100","author":"Sekar","year":"2021","journal-title":"Kidney Int."},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Wu, H.H.L., Kalra, P.A., and Chinnadurai, R. (2021). New-Onset and Relapsed Kidney Histopathology Following COVID-19 Vaccination: A Systematic Review. Vaccines, 9.","DOI":"10.3390\/vaccines9111252"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1053\/j.ajkd.2021.06.016","article-title":"Anca-associated vasculitis following pfizer-biontech COVID-19 vaccine","volume":"78","author":"Shakoor","year":"2021","journal-title":"Am. J. Kidney Dis."},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Sirufo, M.M., Raggiunti, M., Magnanimi, L.M., Ginaldi, L., and De Martinis, M. (2021). Henoch-Sch\u00f6nlein Purpura Following the First Dose of COVID-19 Viral Vector Vaccine: A Case Report. Vaccines, 9.","DOI":"10.3390\/vaccines9101078"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1136\/annrheumdis-2021-220647","article-title":"Immunogenicity and safety of the BNT162b2 mRNA COVID-19 vaccine in adult patients with autoimmune inflammatory rheumatic diseases and in the general population: A multicentre study","volume":"80","author":"Furer","year":"2021","journal-title":"Ann. Rheum. Dis."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.1007\/s00296-021-05017-9","article-title":"Adverse events of six COVID-19 vaccines in patients with autoimmune rheumatic diseases: A cross-sectional study","volume":"41","year":"2021","journal-title":"Rheumatol. Int."},{"key":"ref_15","first-page":"1","article-title":"Eval-uation of antibody response to bnt162b2 mrna COVID-19 vaccine in patients affected by immune-mediated inflammatory dis-eases up to 5 months after vaccination","volume":"5","author":"Firinu","year":"2021","journal-title":"Clin. Exp. Med."}],"container-title":["Vaccines"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2076-393X\/10\/1\/13\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T07:51:57Z","timestamp":1760169117000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2076-393X\/10\/1\/13"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12,23]]},"references-count":15,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,1]]}},"alternative-id":["vaccines10010013"],"URL":"https:\/\/doi.org\/10.3390\/vaccines10010013","relation":{},"ISSN":["2076-393X"],"issn-type":[{"value":"2076-393X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,12,23]]}}}